Growth Metrics

Merck (MRK) Profit After Tax (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -243.15%
Dec 31, 2025 -48.80%
Sep 30, 2025 30.68%
Jun 30, 2025 -12.84%
Mar 31, 2025 36.24%
Dec 31, 2024 17.94%
Sep 30, 2024 -42.12%
Jun 30, 2024 14.68%
Mar 31, 2024 492.26%
Dec 31, 2023 -125.56%
Sep 30, 2023 179.50%
Jun 30, 2023 -311.80%
Mar 31, 2023 -6.50%
Dec 31, 2022 -7.11%
Sep 30, 2022 -17.65%
Jun 30, 2022 -8.43%
Mar 31, 2022 41.03%
Dec 31, 2021 -33.13%
Sep 30, 2021 195.60%
Jun 30, 2021 -43.80%
Mar 31, 2021 205.20%
Dec 31, 2020 -212.44%
Sep 30, 2020 -0.90%
Jun 30, 2020 -27.15%
Mar 31, 2020 271.13%
Dec 31, 2019 -198.64%
Sep 30, 2019 -27.87%
Jun 30, 2019 -9.30%
Mar 31, 2019 63.95%
Dec 31, 2018 -8.82%
Sep 30, 2018 13.64%
Jun 30, 2018 133.15%
Mar 31, 2018 169.30%
Dec 31, 2017 -1,796.43%
Sep 30, 2017 -102.87%
Jun 30, 2017 25.39%
Mar 31, 2017 365.08%
Dec 31, 2016 -126.88%
Sep 30, 2016 81.24%
Jun 30, 2016 6.64%
Mar 31, 2016 15.07%
Dec 31, 2015 -46.22%
Sep 30, 2015 165.79%
Jun 30, 2015 -28.29%
Mar 31, 2015 -86.91%
Dec 31, 2014 717.43%
Sep 30, 2014 -55.34%
Jun 30, 2014 17.54%
Mar 31, 2014 118.31%
Dec 31, 2013 -30.52%
Sep 30, 2013 24.06%
Jun 30, 2013 -43.94%
Mar 31, 2013 70.28%
Dec 31, 2012 -46.17%
Sep 30, 2012 -3.13%
Jun 30, 2012 4.72%
Mar 31, 2012 6.50%
Dec 31, 2011 -5.34%
Sep 30, 2011 -16.07%
Jun 30, 2011 91.78%
Mar 31, 2011 272.46%
Dec 31, 2010 -266.94%
Sep 30, 2010 -52.31%
Jun 30, 2010 136.36%
Mar 31, 2010 -94.94%
Dec 31, 2009 90.48%
Sep 30, 2009 120.03%
Jun 30, 2009 9.21%